Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL2194348 | 0.91 | GAA (0.39) | GAASMN1; SMN2HSD17B3ALDH1A1NOTUM | |
| Acetic Acid SCHEMBL11766149 | 0.89 | GAA (0.38) | GAASMN1; SMN2HSD17B3ALDH1A1NOTUM | |
| Bicarbonate SCHEMBL4853464 | 0.84 | MAOA (0.34) | GAASMN1; SMN2HSD17B3ALDH1A1NOTUM | |
| Bicarbonate SCHEMBL2467504 | 0.84 | MAOA (0.34) | GAASMN1; SMN2HSD17B3ALDH1A1NOTUM | |
| Methyl Alcohol SCHEMBL7362934 | 0.84 | MAOA (0.37) | GAASMN1; SMN2HSD17B3MAOAMAOB | |
| Acetic Acid SCHEMBL10486833 | 0.84 | GAA (0.34) | GAASMN1; SMN2HSD17B3MEN1KMT2A | |
| Acetamide SCHEMBL7696552 | 0.83 | SMN1; SMN2 (0.38) | GAASMN1; SMN2HSD17B3NOTUMNPC1 | |
| Hydrogen Peroxide SCHEMBL15163599 | 0.82 | MAOA (0.38) | GAASMN1; SMN2MAOAMAOB | |
| Acetic Acid SCHEMBL8700134 | 0.81 | GAA (0.36) | GAASMN1; SMN2HSD17B3MEN1KMT2A | |
| Propionic Acid SCHEMBL5157894 | 0.80 | HTT (0.35) | GAASMN1; SMN2HSD17B3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122150-A1 | Pharmaceutical composition and method for treating a joint-capsule arthropathy | JANSSEN PHARMACEUTICA, N.V. (US) | 2006-06-08 | — | — | US | claimed |
| WO-2006039704-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A JOINT CAPSULE ARTHROPATHY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | WO | claimed |
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293374-A1 | Substituted isothiazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
| US-20060122150-A1 | Pharmaceutical composition and method for treating a joint-capsule arthropathy | JANSSEN PHARMACEUTICA, N.V. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006039704-A2 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A JOINT CAPSULE ARTHROPATHY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293374-A1 | Substituted isothiazolones | LTB4R2, PTGES2, CYSLTR2 | GAA 3048/4885SMN1; SMN2 3308/4885HSD17B3 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.